Latest filing published 27 Mar 2026 for Anaptysbio, INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Daniel Faga in Anaptysbio, Inc, where the filings describe the role as chief executive. Over a trading history stretching from 21 March 2022 to 25 March 2026, the count stands at 15 filings.
No open-market purchase appears, only 4 sales worth €3.8M. Other entries cover 5 share grants and 6 option exercises. So far in 2026, the count stands at no purchases and 1 sale.
The newest entry dates from 27 March 2026: a share grant, in Anaptysbio, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations